Latest quarter
Moderna reported Q3 FY2026 revenue of $1.3 billion, above the $888.8 million consensus. Revenue rose 29.2% from $1.0 billion a year earlier; CFO James Mock said higher COVID vaccine sales were the primary driver.
Moderna reported diluted earnings per share of $0.40, compared with −$0.51 a year earlier. Its gross margin fell to 75.8% from 79.6%, while operating margin moved to 9.90% from −25.6%.
Mock said quarterly cost of sales rose as product sales volume and other manufacturing-related costs increased. He also reported lower research and development expenses, attributing the decline to completed or winding-down infectious disease studies and efficiency gains.
Moderna reported free cash flow of −$1.7 billion for the quarter, compared with −$880.0 million a year earlier. Mock said the company ended the quarter with $8 billion in cash and investments, with financing proceeds partly offset by a litigation settlement payment and seasonal working-capital effects.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $1.3 billion | $1.0 billion | 29.2% |
| Diluted EPS | $0.40 | −$0.51 | — |
| Gross margin | 75.8% | 79.6% | −3.8 percentage points |
| Operating margin | 9.90% | −25.6% | 35.5 percentage points |
| Free cash flow | −$1.7 billion | −$880.0 million | — |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Revenue | $1.3 billion | $888.8 million | Beat by 47.7% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
| Against its own guidance | For | Guided | Reported | Result |
|---|---|---|---|---|
| Revenue | Q2 FY2026 | $50.0 million–$100.0 million | $145.0 million | Above the guide |
What management said on the call
CFO James Mock said both U.S. and international revenue came in above the company’s expectations, reflecting “increased demand, operational execution, and timing of shipments between the third and fourth quarters.” He said the U.S. vaccination season was still underway, with increased uptake of mNEXSPIKE and vaccination rates relatively stable against the prior year.
Internationally, Mock pointed to execution in the U.K. and Canada and said year-to-date international revenue of $900 million was already $200 million ahead of the full-year 2025 total. Asked about growth beyond this year, he cited flu, Europe and Latin American partnerships among opportunities for 2027, and said Moderna expected to grow next year.
On costs, Mock said quarterly R&D spending fell as infectious disease studies were completed or wound down. He said Moderna expected higher selling, general and administrative expenses in the fourth quarter, primarily because of commercial activity.
CEO Stéphane Bancel said Moderna raised $3 billion through a 0% convertible note and received approximately $2.6 billion in net proceeds after capped calls and fees. Mock said the quarter-end cash balance also reflected a $950 million litigation settlement payment and seasonal working-capital effects.
Bancel said phase 3 results for intismeran, an individualized cancer therapy being developed with Merck, showed a 42% reduction in the risk of recurrence or death in patients with resected melanoma. He also reported U.S. approval of Moderna’s influenza vaccine mFLUSIVA and Canadian approvals for mFLUSIVA and the combined influenza and COVID-19 vaccine mCOMBRIAX.
Asked about the norovirus program, President Stephen Hoge confirmed that the trial had not met its early-success criteria. He said Moderna would consult regulators rather than proceed with another cohort, adding that an update on potential next steps would follow those discussions. On the U.S. flu-COVID combination vaccine, Hoge said Moderna planned to discuss submission expectations with the FDA.
Guidance
Mock raised Moderna’s FY2026 revenue growth outlook to 15% to 25%, from up to 10%, and lowered expected R&D expenses by $200 million to $2.7 billion. He attributed the R&D change to further study wind-downs and operational efficiencies.
Mock said Moderna now expects $4.5 billion in GAAP operating expenses excluding the litigation charge and $3.8 billion in cash costs. He lowered the capital expenditure estimate to $200 million from a range of $200 million to $300 million.
Moderna projected year-end cash and investments of $8.1 billion to $8.3 billion. Mock said that excluding financing proceeds, the projection would be $5.5 billion to $5.7 billion, versus the previous framework of $4.7 billion to $5.2 billion.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Revenue | FY2027 | Moderna expects to grow in FY2027. | — | — |
| Cash, Cash and Investments | FY2026 | $8.1 billion–$8.3 billion | — | New |
| Capex | FY2026 | $200.0 million | $200.0 million–$300.0 million | Cut |
| Operating expenses, Non Gaap Cash Costs | FY2026 | $3.8 billion | — | New |
| Operating expenses, Non Gaap Excluding Litigation | FY2026 | $4.5 billion | — | New |
| Operating expenses, Sga | Q4 FY2026 | Moderna expects higher SG&A expenses in Q4 FY2026. | — | — |
| Operating expenses, Sga | FY2026 | $1.0 billion | $1.0 billion | Held |
| Research and development | FY2026 | $2.7 billion | $2.9 billion | Cut |
| Operating expenses, Cost of Sales | FY2026 | $1.7 billion | $1.7 billion | Held |
| Gross margin | FY2026 | Moderna expects significant gross margin improvement in FY2026. | — | — |
| Revenue, US International Mix | FY2026 | Moderna expects an approximately even split between U.S. and international revenue in FY2026. | — | — |
| Revenue growth | FY2026 | 15.0%–25.0% | 10.0% | Raised |
| Cash | FY2026 | $8.1 billion–$8.3 billion | $4.5 billion–$5.0 billion | Raised |
| Operating expenses, Selling General and Administrative | FY2026 | $1.0 billion | — | New |
| Revenue, United States | FY2026 | Moderna expects approximately half of its FY2026 revenue to come from the United States. | — | — |
| Cash, Cash and investments | FY2026 | $4.7 billion–$5.2 billion | — | New |
| Operating expenses, Selling, general and administrative | FY2026 | $1.0 billion | — | New |
| Revenue growth, International revenue mix | FY2026 | 50.0% | — | New |
| Revenue growth, U.s. revenue mix | FY2026 | 50.0% | — | New |
| Operating expenses, Cash Costs | FY2026 | $4.0 billion | — | New |
| Operating expenses, Excluding Litigation Charge | FY2026 | $4.7 billion | — | New |
| Debt, Undrawn Credit Facility | FY2026 | $900.0 million | — | New |
| Operating expenses | FY2026 | $4.9 billion | — | New |
| Revenue | H1 2026 | $440.0 million–$490.0 million | — | New |